看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 2.6x - 2.8x | 2.7x |
| Historical Pb Multiple | 2.2x - 23.0x | 3.8x |
| Fair Value | $23.29 - $25.75 | $24.52 |
| Upside | 19.3% - 31.8% | 25.5% |
| Benchmarks | - | Full Ticker |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| CareDx, Inc | - | NasdaqGM:CDNA |
| Vaccinex, Inc. | - | OTCPK:VCNX |
| Monte Rosa Therapeutics, Inc. | - | NasdaqGS:GLUE |
| Coherus BioSciences, Inc. | - | NasdaqGM:CHRS |
| Beam Therapeutics Inc. | - | NasdaqGS:BEAM |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| ONCO | CDNA | VCNX | GLUE | CHRS | BEAM | |||
| NasdaqCM:ONCO | NasdaqGM:CDNA | OTCPK:VCNX | NasdaqGS:GLUE | NasdaqGM:CHRS | NasdaqGS:BEAM | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | -20.5% | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -182.3% | 127.6% | 15.6% | 46.3% | 112.0% | -184.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -19098.5% | -23.1% | -10056.7% | -3968.1% | -49.7% | -273966.1% | ||
| Prior Fiscal Year | NA | -67.9% | -7205.5% | NA | -92.5% | -35.1% | ||
| Latest Fiscal Year | -63986.5% | 15.7% | -3552.8% | -96.1% | 10.7% | -593.1% | ||
| Latest Twelve Months | -2758.7% | 15.7% | -4787.9% | -96.1% | 10.7% | -593.1% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -167.8% | -18.7% | -943.0% | -43.7% | -448.2% | -60.8% | ||
| Prior Fiscal Year | -113.4% | -55.0% | -314.4% | -60.1% | NM | -15.5% | ||
| Latest Twelve Months | -233.8% | 16.4% | NM | -36.2% | NM | -43.9% | ||
| Next Fiscal Year | 159.0% | 8.9% | 244.7% | -88.5% | 69.5% | -88.9% | ||
| Two Fiscal Years Forward | 72.2% | 14.3% | 102.2% | -11803.6% | 37.1% | -1076.7% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.3x | 2.9x | 5.2x | 3.8x | 0.4x | 24.9x | ||
| Price / LTM EPS | 0.0x | 18.7x | -0.1x | -3.9x | 3.3x | -4.2x | ||
| Price / Book | 0.0x | 2.6x | -0.7x | 1.3x | -0.7x | 2.2x | ||
| Price / Fwd Book | 0.0x | 2.4x | 0.1x | 3.3x | -0.3x | 5.6x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -0.7x | 0.0x | 2.6x | |||||
| Historical P/B Ratio | 2.2x | 3.8x | 23.0x | |||||
| Selected P/B Multiple | 2.6x | 2.7x | 2.8x | |||||
| (x) Book Value | 734 | 734 | 734 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ONCO | CDNA | VCNX | GLUE | CHRS | BEAM | |
| Value of Common Equity | 1 | 984 | 2 | 285 | 94 | 1,584 | |
| (/) Shares Outstanding | 8.3 | 55.4 | 2.7 | 61.5 | 115.9 | 81.1 | |
| Implied Stock Price | 0.08 | 17.75 | 0.76 | 4.64 | 0.81 | 19.53 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.08 | 17.75 | 0.76 | 4.64 | 0.81 | 19.53 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |